Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts

Cancer Research

Volumn 60, Issue 21, 2000, Pages 6001-6007

  Reinholz, Gregory G ^a   Getz, Barbara ^a   Pederson, Larry ^a   Sanders, Emily S ^a   Subramaniam, Malayannan ^a   Ingle, James N ^b   Spelsberg, Thomas C ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; DIVALENT CATION; EDETIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; FETUS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; OSTEOBLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN SECRETION;

ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BONE DEVELOPMENT; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CHELATING AGENTS; COLLAGEN; DIPHOSPHONATES; EDETIC ACID; ETIDRONIC ACID; FETUS; GENE EXPRESSION; HUMANS; IMIDAZOLES; OSTEOBLASTS; PROTEINS;

EID: 0034326253     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Bisphosphonates: Mechanisms of action
2. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
3. 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats
4. Bisphosphonates: From the laboratory to the clinic and back again
5. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment
6. The influence of two diphosphonates on calcium metabolism in the rat
7. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis
8. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
9. Comparison of new biochemical markers of bone turnover in late postmenopansal osteoporotic women in response to alendronate treatment
10. The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site
11. 45Ca kinetics in the intact rat
12. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
13. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APK) in rats
14. Changes in bone mineralization, architecture and mechanical properties due to long-term (1 year) administration of pamidronate (APD) to adult dogs
15. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow
16. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages
17. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate
18. Effects of two novel bisphosphonates on bone cells in vitro
19. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism
20. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
21. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment
22. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis
23. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro
24. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts
25. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
26. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
27. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
28. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
29. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
30. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
31. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
32. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
33. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106
34. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
35. 2 synthesis in the clonal osteoblast-like cell line MC3T3-El
36. Tiludronate inhibits interleukin-6 synthesis in osteoblasts: Inhibition of phospholipase D activation in MC3T3-E1 cells
37. Alendronate/interleukin-1β cotreatment increases interleukin-6 in bone and UMR-106 cells: Dose dependence and relationship to the antiresorptive effect of alendronate
38. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells
39. Diphosphonates inhibit human osteoblast secretion and proliferation
40. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors
41. Effect of alendronate on cultured normal human osteoblasts
42. Bisphosphonates stimulate formation of osteoblasts precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteobastogenesis in young and aged mice in vivo
43. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calictonin
44. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line
45. Pharmacokinetics of pamidronate in patients with bone metastases
46. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcemia
47. Pharmacokinetics of pamidronate disodium in cancer patients after single intravenous infusion of 30-, 60-, or 90-mg dose 4 or 24 hours
48. Pamidronate treatment with tumor-associated hypercalcimia: Pharmacological effects and pharmacokinetics
49. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function
50. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
51. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport
52. In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation
53. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
54. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
55. Bisphosphonates inhibit breast cancer cell proliferation and induce cell apoptosis